---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-176795"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:32:20.194678+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Seres increases authorized shares to 240M and updates on Oaktree credit facility tranche conditions

## Summary
- Stockholders approved increase in authorized common shares from 200M to 240M; Certificate of Amendment filed June 27, 2023.
- Company posted updated corporate presentation disclosing funding conditions for Tranche B and Tranche C of Oaktree Credit Facility.
- Management states funding requirements for Tranche B and Tranche C are achievable.

## SEC filing metadata
- accession: 0001193125-23-176795
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523176795/0001193125-23-176795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523176795/d506361d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-176795
- JSON: https://secwatch.observer/filing/0001193125-23-176795.json
- Plain text: https://secwatch.observer/filing/0001193125-23-176795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.